Skip to main content
IMA
NASDAQ Life Sciences

ImageneBio Q3 Loss Widens to $15.6M; Material Weakness Still Unremediated

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$3.97
Mkt Cap
$45.065M
52W Low
$3.88
52W High
$8.84
52W Position info
2.3% above low
Off High info
55% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

IMA is trading near its 52-week low of $3.88 (2.3% above the low).

Summary

ImageneBio posted a $15.6M Q3 net loss and ended September with $126.6M in cash and securities, enough for at least 12 months of operations. The previously disclosed material weakness in internal controls remains unremediated, and $17.0M is still available under its Jefferies ATM.


Key Events · Earnings and Guidance · IMA

  • Q3 Net Loss of $15.6M

    The three-month net loss was $15.6M versus $24.8M a year earlier, when merger-related stock compensation inflated the prior period; nine-month net loss was $36.4M.

  • Cash Down to $126.6M

    Cash, cash equivalents and marketable securities fell to $126.6M at September 30, 2026 from $136.2M at June 30, 2026; management says this funds operations for at least the next 12 months.

  • Material Weakness Unremediated

    Management concluded disclosure controls were not effective as of September 30, 2026 because of a material weakness in segregation of duties over journal entries and account reconciliations, which had not been remediated.

  • $17.0M ATM Still Available

    The August 2026 at-the-market facility with Jefferies has $17.0M of common stock remaining available for sale as of September 30, 2026.


Analysis · IMA · Life Sciences

Cash and investments fell by roughly $9.6M in Q3, leaving ImageneBio with $126.6M at September — enough to fund operations for at least the next 12 months, though the company still expects to need substantial additional capital for its sole clinical asset, olevaprubart. The bigger governance issue: the material weakness in internal controls (incompatible duties over journal entries and account reconciliations) remains unremediated as of September 30, 2026, and management concluded disclosure controls were not effective. With the stock near its 52-week low, the $17.0M at-the-market facility with Jefferies is the near-term dilution lever if the equity market stays closed. Phase 2b atopic dermatitis topline is guided to Q4 2027, and the alopecia areata Phase 2 is expected to start by end-2026.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMA was trading at $3.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.1M. The 52-week trading range was $3.88 to $8.84. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMA - Latest Insights

IMA
Aug 05, 2026, 4:22 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $5.75
Real-time Price: $3.81 info
Change: -$1.94 (-34%) info
Market Cap: $43.249M info
IMA
Aug 05, 2026, 8:10 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.71
Real-time Price: $3.81 info
Change: -$1.90 (-33%) info
Market Cap: $43.249M info
IMA
Aug 05, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.71
Real-time Price: $3.81 info
Change: -$1.90 (-33%) info
Market Cap: $43.249M info
IMA
Aug 05, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.71
Real-time Price: $3.81 info
Change: -$1.90 (-33%) info
Market Cap: $43.249M info
IMA
Jul 23, 2026, 4:28 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $5.57
Real-time Price: $3.81 info
Change: -$1.76 (-32%) info
Market Cap: $43.249M info